$MorphoSys (MOR.US)$ The German pharmaceutical company said ...

Trytosaveabit commented on a stock · Nov 20, 2023 16:01

$MorphoSys(MOR.US)$ The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically significant and clinically meaningful improvement in the portion of patients with a 35% or greater reduction in spleen volume after 24 weeks.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

4933 Views

Comment

Trytosaveabit

1798Followers

29Following

21KVisitors